MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).
Phase:
PHASE3
Details
Lead Sponsor:
Zhongnan Hospital
Collaborators:
Central Hospital of Xiaogan Jingzhou Central Hospital Ruijin Hospital Shanxi Province Cancer Hospital Taihe Hospital The First Affiliated Hospital of Zhengzhou University The First People's Hospital of Jingzhou Xianning Central Hospital Yichang Central People's Hospital